First-in-class inhibitors against respiratory viral infections.

Atriva aims to develop broadly active host cell targeted new antiviral therapies against different respiratory viral infections. Founded in 2015, Atriva attracted seasoned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases. Inhibitors of certain cellular signalling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking viral replication. This creates an unprecedented potential for truly efficacious and safe therapeutics against numerous viral infections. Atriva closed a seed financing of € 3 Mn in late 2016. The proceeds of this allows the company to reach clinical development with its lead project ATR-002 for influenza in high-risk patients.